Oncocross Co.,Ltd. Logo

Oncocross Co.,Ltd.

An AI biotechnology firm that develops drugs by predicting drug-disease interactions.

382150 | KO

Overview

Corporate Details

ISIN(s):
KR7382150001
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로11길 7 905호(문정동, 문정현대지식산업센터1-2), 서울특별시

Description

Oncocross is an artificial intelligence (AI) biotechnology company specializing in drug development. The company utilizes proprietary AI platforms, including RAPTOR AI™, which analyze a comprehensive, medically curated transcriptome database of patients, drugs, and diseases. This technology is used to predict interactions between drugs and diseases, enabling the identification of optimal indications for new and existing compounds. Oncocross focuses on developing treatments for cancer, rare diseases, and other intractable conditions. Its approach aims to accelerate the drug development process, reduce costs, and increase the success rate of clinical trials by identifying promising drug candidates and expanding their potential applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-04-01 00:00
사업보고서 (2023.12)
Korean 1.4 MB
2023-11-14 00:00
분기보고서 (2023.09)
Korean 1.1 MB
2023-11-14 00:00
[기재정정]분기보고서 (2023.09)
Korean 1.2 MB
2023-11-10 00:00
증권발행실적보고서
Korean 48.1 KB
2023-11-09 00:00
투자설명서
Korean 1.7 MB
2023-11-08 00:00
[기재정정]증권신고서(지분증권)
Korean 1.7 MB
2023-10-30 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 71.0 KB
2023-10-30 00:00
[기재정정]증권신고서(지분증권)
Korean 1.9 MB
2023-10-19 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 89.7 KB
2023-10-19 00:00
[기재정정]증권신고서(지분증권)
Korean 2.5 MB
2023-09-26 00:00
주요사항보고서(유상증자결정)
Korean 68.1 KB
2023-09-26 00:00
증권신고서(지분증권)
Korean 1.5 MB
2023-08-11 00:00
반기보고서 (2023.06)
Korean 1.0 MB
2023-05-15 00:00
분기보고서 (2023.03)
Korean 1.0 MB
2023-03-31 00:00
사업보고서 (2022.12)
Korean 1.3 MB

Automate Your Workflow. Get a real-time feed of all Oncocross Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncocross Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncocross Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.